Advanced development and validation of aliquot-level visual indicators of biospecimen exposure to thawed conditions

Active Grant Awarded

Award ID
R33CA309724
Recipient
Awarding agency
Obligated
$353,601

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 18% complete
Place of performance
Tempe, AZ 85287, USA

Award details come from USAspending.gov.

About this award

The National Cancer Institute, within the Department of Health and Human Services National Institutes of Health, awarded Arizona State University $353,601 in obligated funds on May 8, 2026, under Cancer Treatment Research (Assistance Listing 93.395), for advanced development and validation of aliquot-level visual indicators of biospecimen exposure to thawed conditions. The assistance type is Grant, the ultimate completion date is April 30, 2029, and place of performance is Tempe, Arizona.

The indicators build on the color-changing permanganate/oxalate reaction in melting point-depressed aqueous solvents, which the principal investigator's laboratory began developing under a 2022 R21 award from the NCI's IMAT program. The reaction is designed as a user-friendly, inexpensive visual tracker with temperature thresholds as low as -18 C, -37 C, and -67 C.

Arizona State University passed a portion of the work to Wainamics, Inc., a minority-owned, woman-owned, and economically disadvantaged small business in Pleasanton, California, under sub-award R33CA309724-ASUB00002297, dated September 18, 2026, which carries the same project title. The vendor profile describes Wainamics' grant sub-awards as microfluidic cartridge and CRISPR diagnostic work, including cartridge optimization for saliva sample processing, optical data collection, on-cartridge assay optimization, and design transfer to injection molding, coordinated with the Doudna Lab and Fusion Biotec.

Description

Abstract
Many biological analytes of interest to both clinical oncologists and cancer researchers are unstable when the unfixed biospecimens in which they reside are exposed to thawed conditions. For example, american society of clinical oncology / college of american pathologists guidelines state that the post-excision-up-to-fixation exposure time span for tissues collected for clinical HER2 testing in breast cancer must be less than 1 hour. For blood plasma/serum and many types of tissue specimens that are to be frozen, the proper cold storage temperature is well below the common laboratory freezer temperature of -20 °C. For this and many other reasons, every year improprieties and inconsistencies in pre-analytical sample handling and storage generate unacceptably large numbers of costly false leads in biomedical research. Unsurprisingly, experts in the field agree that this problem must be minimized immediately. Currently there are few tools and not so much as one widely accepted approach by which to implement evidence-based tracking of biospecimen exposure to thawed conditions. In practice, IT is actually quite rare for biomedical researchers to employ any evidence-based QA/QC tools at all-which suggests that easy-to-use, individual aliquot-level thawed-state indicators could have a major impact on improving biospecimen quality tracking and therefore actual biospecimen quality. In 2022, the PI's lab was awarded an R21 grant through the NCI's imat program to pursue development of the kinetically unique, autocatalytic, color-changing permanganate/oxalate reaction in melting point-depressed aqueous solvents as simple (i.e., user friendly), inexpensive, visual trackers of biospecimen exposure to inappropriately warm conditions, including temperature thresholds as low as -18 °C, -37 °C and -67 °C. The chemistry for 14 targeted time-temperature indicators (TTIS) has been successfully developed. Under this proposed project, the PI's lab seeks to maximize the color intensity of the TTIS (advanced development) and to develop and validate user-friendly, self-contained, customer-activatable physical devices that will ultimately translate the unique chemistry that underpins the TTIS into market-ready products that provide aliquot-level color-changing indicators of biospecimen exposure to thawed or inappropriately warm conditions that make IT essentially impossible for anyone handling the specimens to ignore their integrity status. This will be accomplished under two specific aims: specific aim 1: leverage our recently developed, AI-enabled chemical kinetics simulations to develop and validate permanganate/oxalate reaction-based TTIS with maxed-out, 5X color intensity that run for as little as 5 minutes to as long as 2.5 HRS at 25 °C-and that have melting points of 0 °C, -18 °C, -37 °C, or -67 °C. Specific aim 2: develop and performance-test several physical device designs that will provide self-contained, aliquot-level, user-activatable, color-changing TTI devices that anyone can use to track the exposure of biospecimens to thawed / inappropriately warm conditions.

Subawards

Subrecipient Amount Awarded
Wainamics, Inc. Advanced development and validation of aliquot-level visual indicators of biospecimen exposure to thawed conditions $119,804

Quick answers

Who received award R33CA309724?

R33CA309724 was awarded to Arizona State University by National Cancer Institute (National Institutes of Health) on May 8, 2026.

How much is award R33CA309724 worth?

$353,601 has been obligated on R33CA309724.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award